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Abstract
Background: Histamine is commonly acknowledged as an inflammatory mediator in peripheral tissues, leaving its
role in brain immune responses scarcely studied. Therefore, our aim was to uncover the cellular and molecular
mechanisms elicited by this molecule and its receptors in microglia-induced inflammation by evaluating cell
migration and inflammatory mediator release.
Methods: Firstly, we detected the expression of all known histamine receptor subtypes (H1R, H2R, H3R and H4R),
using a murine microglial cell line and primary microglia cell cultures from rat cortex, by real-time PCR analysis,
immunocytochemistry and Western blotting. Then, we evaluated the role of histamine in microglial cell motility by
performing scratch wound assays. Results were further confirmed using murine cortex explants. Finally, interleukin-
1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels were evaluated by ELISA measurements to determine
the role of histamine on the release of these inflammatory mediators.
Results: After 12 h of treatment, 100 μM histamine and 10 μg/ml histamine-loaded poly (lactic-co-glycolic acid)
microparticles significantly stimulated microglia motility via H4R activation. In addition, migration involves α5β1
integrins, and p38 and Akt signaling pathways. Migration of microglial cells was also enhanced in the presence of
lipopolysaccharide (LPS, 100 ng/ml), used as a positive control. Importantly, histamine inhibited LPS-stimulated
migration via H4R activation. Histamine or H4R agonist also inhibited LPS-induced IL-1β release in both N9 microglia
cell line and hippocampal organotypic slice cultures.
Conclusions: To our knowledge, we are the first to show a dual role of histamine in the modulation of microglial
inflammatory responses. Altogether, our data suggest that histamine per se triggers microglia motility, whereas
histamine impedes LPS-induced microglia migration and IL-1β release. This last datum assigns a new putative anti-
inflammatory role for histamine, acting via H4R to restrain exacerbated microglial responses under inflammatory
challenge, which could have strong repercussions in the treatment of CNS disorders accompanied by microglia-
derived inflammation.
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Background
Microglial cells play a pivotal role in the immune surveil-
lance of the central nervous system (CNS) by avidly sur-
veying the brain parenchyma in search of infection, injury,
or other sources of pathology [1,2]. In this sense, micro-
glial cells become activated and migrate to the injury site
in order to fully develop a concerted immune response, in-
volving the release of both trophic and pro-inflammatory
factors [1]. The study of the classical components that
constitute the microglia response in the inflammatory
process has been copiously supported by the use of lipo-
polysaccharide (LPS), a gram-negative cell wall compo-
nent. LPS binds to the CD14/TLR4/MD2 receptor
complex, located on the cell membrane, triggering clas-
sical microglial responses such as proliferation, migration,
phagocytosis and release of inflammatory mediators [3,4].
Histamine is an endogenous biogenic amine mostly stored
in the granules of mast cells and basophils that readily re-
lease their content upon stimulation [5]. Other sources of
histamine include histaminergic neurons, gastric entero-
chromaffin-like cells, leukocytes and platelets, to name a
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few. Moreover, in the CNS, histamine is released by
microglial cells [6]. Histamine exerts its various functions
through the activation of four distinct subtypes of G-pro-
tein coupled receptors: H1 receptor (H1R), H2 receptor
(H2R), H3 receptor (H3R) and H4 receptor (H4R) [7]. Their
actions range mainly from the modulation of the allergic
reaction (H1R), regulation of heart and gastric acid secre-
tion (H2R) to neurotransmitter release (H3R). H4R is
mainly expressed by cells of the immune system (e.g., B-
and T-lymphocytes, dendritic cells, eosinophils, fibro-
blasts, mast cells, monocytes, natural killer cells and neu-
trophils), and its expression is modulated by an
inflammatory context [8]. At the moment, H4R is primar-
ily known for its chemotactic effect on mast cells and eosi-
nophils (reviewed by [9]).
In our study, we showed for the first time that all known
histamine receptors are expressed in microglial cells. We
also showed that histamine per se stimulates microglia mo-
tility. However, and most interestingly, in an LPS-induced
inflammatory context, histamine has an inhibitory action in
microglia migration and in the release of interleukin-1beta
(IL-1β). In summary, we uncovered a novel dual role for
histamine in the regulation of neuroinflammation mediated
by microglia activity by modulating cell recruitment and
the release of pro-inflammatory cytokines, such as IL-1β
and tumor necrosis factor-alpha (TNF)-α.
Methods
All experiments were performed in accordance with Euro-
pean Union (2010/63/EU) guidelines for the care and use
of laboratory animals. All efforts were made to minimize
animal suffering and the number of animals used.
Cell line culture
The murine N9 microglia cell line (a kind gift from Prof.
Claudia Verderio, CNR Institute of Neuroscience, Cellular
and Molecular Pharmacology, Milan, Italy) was grown as
previously described [10]. Cells were plated at a density of
2 × 104 cells per well in 24-well trays (immunocytochem-
istry), 5 × 104 cells per well in 12-well trays (scratch wound
assays) or plated at a density of 5 × 105 cells per well in 6-
well trays (for the remaining experiments). Cell treatments
included the following incubation setup: histamine dihy-
drochloride (1–100 μM, Sigma), LPS (100 ng/ml, Sigma),
α5β1 blocking antibody (10 μg/ml, Millipore Corp., Bed-
ford, MA, USA), H1 receptor antagonist, 2-((2-(dimethyla-
mino)ethyl)(p-methoxybenzyl)amino)-pyridine maleate
(mepyramine maleate, 1 μM), H2 receptor antagonist, N-
cyano-N’-methyl-N”-[2-[(5-methyl-1 H-imidazol-4-yl)me-
thyl]thio]ethyl]guanidine (cimetidine, 5 μM), H3 receptor
antagonist 3-amino-N-[2-(1 H-imidazol-4-yl)ethyl]propa-
namide ditrifluoroacetate (carcinine ditrifluoroacetate, 5
μM), H4 receptor antagonist, 1-[(5-chloro-1 H-indol-2-yl)
carbonyl]-4-methylpiperazine (JNJ7777120, 5 μM) and H4
receptor agonist, 5-(2-aminoethyl)-4-methylimidazole
dihydrochloride (4-methylhistamine dihydrochloride, 20
μM) (all from Tocris, Ballwin, MO, USA) for 3 h (receptor
expression evaluation), 6 h (cytokine release) or 12 h (mi-
gration studies). Wortmanin (50 nM, Alomone Labs Ltd.,
Jerusalem, Israel), p38 inhibitor SB239063 (20 μM, Sigma)
and all histamine receptor antagonists/agonists were
added 40 min prior to cell treatment.
Primary microglia cell cultures from cortex
Mixed glial cultures from the cortex were prepared as pre-
viously described by Saura and colleagues (2003) [11].
Briefly, neonatal Wistar rats (P2-4) were killed, and the
brains were placed in ice-cold 0.15 M sterile PBS. After re-
moval of the meninges, cortex explants were digested in
cysteine solution (1.9 mM CaCl2, 1.3 mM cysteine) and
H&B solution (116 mM NaCl, 5.4 mM KCl, 26 mM
NaHCO3, 12 mM NaH2PO4.H2O, 1 mM MgSO4.7H2O, 0.5
mM EDTA, 25 mM glicose, pH 7.3) supplemented with 20
U/ml papain and 0.001% phenol red at 37°C for 4 min,
under constant agitation. Then, the tissue was rinsed with
high glucose Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen, Paisley, UK) supplemented with 10% fetal bo-
vine serum (FBS), 100 U/ml penicillin and 100 μg/ml
streptomycin. After mechanical dissociation, cells were pel-
leted by centrifugation (3 min, 405× g; 3K18C Bioblock Sci-
entific; Sigma Laboratory Centrifuges) and suspended in
DMEM. The cells were then plated into 12-well cell culture
plates at a density of 0.087×106 cells per well. The cultures
were kept at 37°C in a 5% CO2 and 95% air atmosphere,
and the cell medium was changed every 7 days. On day
20–21, a mild trypsinization (trypsin dilution 1:3 in DMEM
without FBS) was done for 40 min at 37°C to remove astro-
cytes. The resultant adherent microglial cells were washed
twice with DMEM and kept at 37°C in a 5% CO2 and 95%
air atmosphere for a further 5 days before RT-PCR and
Western blot experiments. More than 98% of the cells in
culture were immunopositive for the microglia marker
CD11b.
Brain cortex explants
Adult wild-type (WT) C57BL6 mice were used for the
study of cell motility in cortex explants. Briefly, mice
were killed, and the brains were placed in Hank’s
balanced salt solution (HBSS), supplemented with 100
U/ml penicillin and 100 μg/ml streptomycin (all from
Invitrogen). After removal of the meninges, cortex
explants (spanning all cortical layers) were dissected
from 400-μm-thick coronal sections using a tissue chop-
per under a stereoscopic microscope and placed indi-
vidually over poly-D-lysine-coated (0.1 mg/ml) glass
coverslips in 12-well cell culture plates. Explants were
allowed to adhere for 4 h before the medium was
replaced to Opti-MEM (50%), heat-inactivated horse
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serum (25%) and HBSS (25%), supplemented with D-
glucose to a final concentration of 25 mM and 100 U/ml
penicillin and 100 μg/ml streptomycin (all from Invitro-
gen). The motility assay occurred for 24 h, after medium
replacement, at 5% CO2 and 95% atmospheric air at 37°
C, before fixation.
Results are expressed as the number of CD11b-posi-
tive cells, denoting microglial and/or CNS macrophages,
that migrated from the explants within a 300-μm radius
from the explant edge and normalized per explant area
(number of CD11b-positive cells/mm2). Cell migration
was only evaluated in explants with an area ranging
from 1 to 1.5 mm2. Explant images were acquired using
MetaFluor Software (Universal Imaging, Downingtown,
PA, USA), and the explant area and radius were analyzed
with NIH ImageJ Software.
Organotypic hippocampal slice cultures
Briefly, 7-day-old C57BL6 WT mice were killed by de-
capitation, their brains removed under sterile conditions,
and the hippocampi isolated and cut in 350-μm coronal
sections using a McIlwain tissue chopper. Individual
slices were placed in ice-cold Gey’s balanced salt solu-
tion (Biological Industries, Israel) supplemented with 25
mM D-glucose (Merck, Darmstadt, Germany), 100 U/ml
penicillin and 100 μg/ml streptomycin, before being
placed on porous insert membranes (Millipore Corp.).
Six slices were put onto each membrane, and the inserts
were transferred to a six-well culture tray (Corning
Costar, Corning, NY, USA). Each well contained 1 ml
culture medium, composed of 50% Opti-minimal essen-
tial medium, 25% heat-inactivated horse serum, and 25%
HBSS supplemented with 25 mM D-glucose, 50 U/ml
penicillin and 50 μg/ml streptomycin (all from Invitro-
gen). Slices were allowed to grow for 2 weeks before the
ELISA experiments.
Real-time polymerase chain reaction analysis of histamine
receptors expression
Total RNA was isolated from the N9 murine microglial
cell line, from primary microglia cell cultures from the
cortex and from hippocampal extracts (positive control)
according to the illustra RNAspin Mini RNA Isolation
Kit manufacturer’s instructions (GE Healthcare Life
Sciences, Buckinghamshire, UK). Precipitated RNA was
resuspended in 20 μl of diethylpyrocarbonate (DEPC)-
treated water and quantified by optical density (Nano-
Drop 2000, ThermoScientific, Waltham, MA, USA). For
cDNA synthesis, 2 μg of total RNA was mixed with 2.5
μM anchored-oligo-p(dT)18 primers, 1× PCR reaction
buffer, 20 U RNase inhibitor, dNTPs (1 mM each) and
10 U AMV Reverse Transcriptase in a 20-μl final volume
(Roche Molecular Biochemicals). The reaction was per-
formed at 55°C for 30 min and stopped by 85°C for a 5-
min step. For gene expression analysis, 1 μl of sample
cDNA was added to 10 μl EvaGreen Supermix (BioRad,
Hercules, CA, USA), and the final concentration of each
primer was 10 μM in 20 μl total reaction volume. The
thermocycling reaction was initiated with activation of
Taq DNA polymerase by heating at 94°C for 3 min, fol-
lowed by 30 cycles of a 15-s denaturation step at 94°C,
and a 30 s annealing and elongation step at 57°C for all
sets of primers. For housekeeping gene hypoxanthine
phosphoribosyltransferase 1 (HPRT-1), primer sets were
obtained from selected QuantiTect Primer Assays (Qia-
gen, Austin, Texas). Fluorescence was measured after
the extension step by the iQ5 Multicolor Real-Time PCR
Detection System (BioRad). After the thermocycling re-
action, the melting step was performed with slow heat-
ing, starting at 55°C and with a rate of 0.5°C per 10 s, up
to 95°C, with continuous measurement of fluorescence,
allowing detection of possible nonspecific products. The
assay included a non-template control (sample was sub-
stituted by sterile water), a negative transcriptase reac-
tion sample and a standard curve (in 10-fold steps) of
DNA for assessing the efficiency of each set of primers.
All reactions were run in duplicates. Ct values were
measured in the exponential phase and were set at the
same fluorescence value in each run performed. ΔCt was
calculated by subtracting each Ct sample from in-plate
Ct of the housekeeping reference gene HPRT-1. A smal-
ler ΔCt value represents higher gene expression. Data
analysis was performed with Biorad iQ5 software
(BioRad). The PCR products were subjected to electro-
phoresis in a 1% agarose gel stained with ethidium
bromide. Digital photographs were taken in a Versa-Doc
Imaging System (Model 3000, BioRad).
Primer sequences: H1R, forward primer 5’-GGG CTC
AAA GGC CAA TGA C-3’ and reverse primer 5’-TCC
GCC GGC AAG TAC TCA-3’ (74 bp); H2R, forward
primer 5’-CTG GCT GTC AGC TTG AAT CG-3’ and
reverse primer 5’-GCT GCC AGG GAC ACA ATG A-3’
(65 bp); H3R, forward primer 5’-CTT CTC TCT CCC
AAG ACG ATC TG-3’ and reverse primer 5’-GGC TCC
GGG ATT AAG GAA GA-3’ (65 bp); H4R, forward pri-
mer 5’-GCT ACG ATC GAT ACC AGT CA-3’ and re-
verse primer 5’-AAG AAA GCC AGT ATC CAA ACA
G-3’ (109 bp) (synthesized by Eurofins MWG Operon,
Ebersberg, Germany).
Preparation and characterization of PLGA microparticles
The single emulsion technique was used to prepare
microparticles of approximately 2 μm in diameter. PLGA
(resomer 752 H) (100 mg; Boehringer Mannheim;
Mannheim) was dissolved in 2.5 ml of a solvent mixture
(1:4 methylene chloride: trifluoroethanol), and 5 mg his-
tamine was added. This solution was added to a stirred
chilled polyvinyl alcohol (PVA) solution [100 ml, 5% (w/
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v)]. The resulting suspension was stirred for 3 h, washed
with distilled water and finally freeze-dried. The morph-
ology and diameter of PLGA particles were evaluated by
scanning electron microscopy according to our previous
reports [12]. Release experiments in 0.15 M PBS at 37°C
were performed in order to evaluate the release profile
of histamine over 30 days and to assess the loading effi-
ciency of the microparticles. The loading capacity of
PLGA microparticles was approximately 5.3 μg of hista-
mine per mg of microparticles. Approximately 1 μg of
histamine was released per mg of microparticles over 4
days [13]. Blank microparticles, i.e., without histamine,
were also prepared to test the effect of the microparticle
formulation per se [13].
Motility assay
Before N9 microglial cell seeding, two parallel lines were
carved on the underside of each well with a scalpel.
These lines served as a guidance axis together with the
line provided by the scratch wound. The cell monolayer
was approximately 95% confluent before the migration
assay took place. One hour before performing the
wound, medium was replaced by serum-free medium to
ensure no proliferation occurred during experiments.
The wound was made by a perpendicular scratch made
with a P10 pipette tip (Gilson S.A.S., Villiers-le-Bel,
France). After N9 microglial cell treatment, images were
taken with an inverted Axiovert 200 microscope (Carl
Zeiss, Göttingen, Germany), with a 5× objective and a
CoolSNAP digital camera (Roper Scientific, Tucson, AZ,
USA). Differential interference contrast (DIC) images
were acquired using MetaFluor Software (Universal Im-
aging, Downingtown, PA, USA) and analyzed with NIH
ImageJ Software. For the N9 microglia cell line, cell mo-
tility was determined by counting the number of cells
that migrated towards the middle of the wound within a
12-h period of treatment. The protocol was adapted
from Valster and colleagues (2005) [14].
Enzyme-linked immunosorbent assay for IL-1β
Cells were plated and treated as described above (see
section Cell line culture). Cells were left at room
temperature (RT) for 5 min in lysis buffer [137 mM
NaCl, 20 mM Tris–HCl, 1% Triton X-100, 10% glycerol,
1 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml
aprotinin, 1 μg/ml leupeptin, 0.5 mM sodium orthovana-
date (all from Sigma), pH 8.0]. Total protein concentra-
tion was determined by the bicinchoninic acid method
(BCA), and samples were stored at −80°C. For the quan-
tification of IL-1β protein levels, a mouse IL-1β ELISA
kit was used following the manufacturer’s instructions
(eBioscience, San Diego, CA). For that purpose, Microti-
ter plates (MaxiSorp, Nunc A/S, Roskilde, Denmark)
were used. Optical density was recorded at 450 and 570
nm (values later subtracted from those obtained with
450 nm) in an ELISA plate (SPECTRA max 384 Plus,
Molecular Devices).
Enzyme-linked immunosorbent assay for TNF-α
Cells were plated and treated as described above (see
section Cell line culture). After cell lysis and protein
quantification, as described above (see section Enzyme-
linked immunosorbent assay for IL-1β), a mouse TNF-α
ELISA kit was used according to the manufacturer’s
instructions (eBioscience). Optical density was recorded
at 450 and 620 nm (values later subtracted from those
obtained with 450 nm) in an ELISA plate (SPECTRA
max 384 Plus, Molecular Devices).
Western blotting
For total extracts, cells were incubated with lysis cocktail
solution [137 mM NaCl, 20 mM Tris–HCl, 1% Triton X-
100, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride,
10 μg/ml aprotinin, 1 μg/ml leupeptin, 0.5 mM sodium
vanadate (all from Sigma), pH 8.0]. Samples were centri-
fuged for 20 min at 4,300 g at 4°C, and the supernatant
collected.
The total amount of protein was quantified using the
BCA assay. Afterwards, 50-μg samples were loaded onto
12% acrylamide/bisacrilamide gels (BioRad). Proteins were
separated by SDS-PAGE using a bicine/SDS (Sigma) elec-
trophoresis buffer (pH 8.3) and then transferred to PVDF
membranes (Millipore) on the following conditions: 300
mA, 90 min at 4°C in a solution containing 10 mM CAPS
and 20% methanol, pH 11.0). Membranes were blocked in
Tris-buffer saline containing 5% BSA and 0.1% TweenW
20 (Sigma) for 1 h, at RT, and then incubated overnight at
4°C with the primary antibody solution diluted in 0.1%
TBS-Tween, 5% BSA. The following primary antibodies
were used: goat polyclonal anti-H4 receptor (1:5,000, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and
mouse monoclonal anti-GAPDH (1:10,000, Millipore) (all
from Cell Signaling). After rinsing with TBS-T, mem-
branes were incubated for 1 h at RT with an alkaline phos-
phatase-linked secondary antibody anti-goat or anti-
mouse IgG 1:10,000, in 5% BSA, 0.1% TweenW 20 (Sigma)
and 1% TBS-T (GE Healthcare UK Limited, Buckingham-
shire, UK). Protein immunoreactive bands were visualized
in a Versa-Doc Imaging System (Model 3000, BioRad),
after incubation of the membrane with ECF reagent (GE
Healthcare UK Limited) for 5 min.
Immunocytochemistry
Cells were fixed with 4% PFA, and unspecific binding
was prevented by incubating cells in a 3% BSA and 0.1%
Triton X-100 solution for 30 min at RT. Cells were kept
overnight at 4°C in blocking solution with the primary
antibodies, then washed with 0.15 M PBS and incubated
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for 2 h at RT with the corresponding secondary anti-
body. Antibodies were used as listed: goat polyclonal
anti-H4 receptor (1:5,000, Santa Cruz Biotechnology,
Inc., CA, USA), rat monoclonal anti-CD11b (1:1,000,
AbD Serotec, Oxfordshire, UK) and rat monoclonal
α5β1 antibody (10 μg/ml, Millipore) in 0.1% Triton X-
100, 0.3% BSA solution; Alexa Fluor 594 donkey anti-
goat and Alexa Fluor 488 goat anti-rat (all 1:200 in PBS,
from Molecular Probes, Eugene, OR, USA). For nuclear
labeling, cell preparations were counterstained with
Hoechst 33342 (2 μg/ml) (Molecular Probes) in 0.15 M
PBS for 5 min at RT and mounted in Dakocytomation
fluorescent medium (Dakocytomation Inc.). Fluorescent
images were acquired using a confocal microscope with
a Plan-ApoChromat 63×/1.40 oil objective (N9 micro-
glial cells) or Plan-ApoChromat 40×/1.3 oil objective
(cortex explants) (LSM 510 Meta, Carl Zeiss).
Data analysis
Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software, San Diego, CA). Statistical signifi-
cance was considered relevant for p values< 0.05 using
one-way analysis of variance followed by Bonferroni’s post
hoc test for comparison among experimental settings and
Dunnett’s post hoc test for comparison with control con-
ditions. Data were presented as means ± standard error of
mean (SEM). For the N9 microglia cell line motility assay,
four images per experimental condition were acquired.
For cortex explants, a series of images around the whole
specimen were taken to count every cell within a 300-μm
radius from the explants. Every experimental condition
was tested in three sets of independent experiments, un-
less stated otherwise, and performed in duplicates.
Results
Microglial cells express histamine H4 receptor
In this work, we studied the role of histamine in micro-
glial-induced inflammatory responses, and for that pur-
pose, we used complementary approaches using a
murine microglia cell line, primary microglia cultures
from the cortex, hippocampal organotypic slice cultures
and cortex explants. We previously validated the use of
the N9 cell line in the study of microglial responses by
showing that neuropeptide Y dampens both LPS- and
IL-1β-stimulated cell migration, phagocytosis and the re-
lease of potent pro-inflammatory mediators [10,15,16].
Firstly, we performed real-time polymerase chain reac-
tion (qPCR) to identify the expression of all known his-
tamine receptors. In that sense, we amplified cDNA
coding for H1R, H2R, H3R and H4R, and normalized the
relative expression of each gene against a previously
selected housekeeping gene, hypoxanthine phosphoribo-
syltransferase 1 (HPRT-1) [17]. We found that N9 micro-
glial cells expressed low basal levels of H1R, H2R and H3R,
whereas H4R appeared to be more abundantly expressed
(ΔCtH1R=13.4 ± 0.7; ΔCtH2R= 15.0± 1.3; ΔCtH3R=16.4
± 2.3; ΔCtH4R=13.0± 0.3; n = 3-4) (Figure 1A). A smaller
ΔCt value represents higher gene expression. Negative
controls showed no amplification (data not shown). H4R
is mainly expressed by cells of the immune system. Since
its role in the CNS has been poorly discussed, and to our
knowledge, we are the first to report H4R expression by
microglial cells, we then focused our study on this recep-
tor [8,18]. Accordingly, we performed Western blotting to
determine whether differences regarding the pattern of re-
ceptor expression existed in an inflammatory context.
Interestingly, LPS challenge (100 ng/ml, for 12 h) did not
alter H4R protein expression by N9 microglial cells
(Figure 1B). For both experimental approaches, primary
microglia cultures obtained from the cortex (Cx) were
used as positive controls. Furthermore, for qPCR analysis
we also used whole hippocampus cDNA as a positive con-
trol [19] (data not shown). Then, we confirmed by im-
munocytochemistry that both N9 microglial cells (top
panel) and cortex primary microglia cell cultures (bottom
panel) expressed H4R (in red), in a similar fashion, in con-
trol conditions and under LPS challenge (Figure 1C). As a
positive control, coronal brain slices were used for H4R-
positive immunodetection on the hippocampus [19] (data
not shown). To visualize cell morphology we labeled the
alpha chain of αMβ2-integrin, CD11b (in green), a well-
known surface marker for microglia and leukocytes,
whose over-expression is associated to microglial and/or
CNS macrophage activation [20].
Histamine induces microglia motility through H4R
activation
To evaluate the effect of histamine on microglia motility,
we determined the number of N9 microglial cells that
migrated in vitro across a scratch wound (Figures 2, 3, 4, 5).
Accordingly, we performed a dose–response curve to assess
a functionally relevant concentration of histamine (Fig-
ure 2A). Microglial cells were treated for 12 h with concen-
trations of histamine ranging from 1 to 100 μM, and we
observed that only 100 μM histamine significantly
induced cell motility (meanCTR = 101.9 ± 4.9 cells;
meanHIS100μM= 174.4 ± 5.9 cells; p< 0.001, n = 13-20).
At this concentration, histamine did not interfere with
microglia cell death or proliferation (data not shown).
We also developed histamine-loaded poly (lactic-co-
glycolic acid) (PLGA) microparticles in order to pro-
mote a more efficient and controlled delivery of hista-
mine in the cell culture medium. Histamine in solution
can be rapidly degraded, posing difficulties in the deliv-
ery of therapeutic doses in an in vivo approach. We
were the first to develop histamine-loaded microparti-
cles as a powerful strategy to overcome these limita-
tions by ensuring local and continuous (up to 30 days)
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Figure 1 Microglial cells express histamine receptors. (A) Histamine receptor expression analysis by real-time PCR showed that microglial cells
constitutively express all known histamine receptors – H1R (74 bp), H2R (65 bp), H3R (65 bp) and H4R (109 bp). (B) LPS stimulation (100 ng/ml) did not alter
the expression of H4R, quantified by Western blotting. Data are expressed as percentage of control (n=3-4). A representative blot is shown below the
graph (H4R, 44 kDa; GAPDH, 37 kDa). In both experimental paradigms, primary microglia cultures from the cortex (Cx) were used as a positive control. For
qPCR, whole hippocampal cDNA was used as an additional positive control (data not shown). (C) N9 microglial cells (top panel) and primary cortical
microglia cultures (bottom panel) expressed H4R (in red) under control conditions and upon LPS challenge (100 ng/ml). Cells were stained for morphology
marker CD11b (in green) and Hoechst 33342 (nuclei in blue). Scale bar, 10 μm.
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extracellular release of histamine [13]. In previous work
by our group, histamine-loaded PLGA microparticles
were shown to efficiently promote neurogenesis with-
out any cytotoxic effect [13]. Accordingly, 10 μg/ml his-
tamine-loaded microparticles significantly promoted
cell motility, whereas blank (void formulation) particles
had no effect (meanuP10μg/ml = 166.4 ± 19.7 cells; mean-
blank = 107.7 ± 3.2 cells; p< 0.01, n = 3-4). LPS challenge
(100 ng/ml) was used as a positive control (meanLPS =
167.0 ± 11.2 cells; p< 0.001, n = 13) (Figure 2A). To un-
cover which histamine receptor was involved, we trea-
ted N9 microglial cells with histamine (100 μM)
together with an antagonist for each receptor individu-
ally (data not shown), and only H4R antagonist
(JNJ7777120, 5 μM) significantly reduced histamine-
induced migration (meanHIS+H4R ant = 93.5 ± 11.1 cells;
p< 0.001, n = 4). Moreover, the simultaneous blockade
of other receptors [H1R antagonist, mepyramine male-
ate (1 μM), H2R antagonist, cimetidine (5 μM) and H3R
antagonist, carcinine ditrifluoroacetate (5 μM)] did not
abolish histamine-induced migration (meanHIS+AntH1,2,3R =
142.6 ± 12.8 cells; p< 0.05, n=4). Noteworthily, applica-
tion of an H4R agonist (4-methylhistamine dihydrochlor-
ide, 20 μM) mimicked the effect induced by histamine per
se (meanH4R ag = 159.2 ± 9.3 cells; p< 0.05, n=8) (Fig-
ure 2B). Representative digital images depict the migratory
effect induced by histamine through the activation of H4R
(Figure 2C). These data suggest that histamine per se
induced microglia motility via H4R activation.
Histamine-induced migration requires α5β1 integrin
signaling
An important feature for cell motility to occur is the
presence of membrane integrins that promote the
Figure 2 (See legend on next column)
(See figure on the previous column)
Figure 2 Histamine induces microglia migration via H4 receptor
activation. (A) Within the range of concentrations tested, only 100
μM histamine significantly induced microglia motility. Moreover, 10
μg/ml histamine-loaded PLGA microparticles (μP, 10 μg/ml)
mimicked the effect of 100 μM histamine, whereas blank
microparticles did not enhance motility. (B) Histamine-induced
motility was inhibited in the presence of H4R antagonist (Ant H4R:
JNJ7777120, 5 μM). Accordingly, H4R agonist application (Ag H4R: 4-
methylhistamine dihydrochloride, 20 μM) resembled histamine
treatment. The involvement of other receptors was excluded since
the application of their respective antagonists did not interfere with
the migration-inducing effect of histamine [H1R antagonist
(mepyramine maleate), 1 μM; H2R antagonist (cimetidine), 5 μM; H3R
antagonist (carcinine ditrifluoroacetate), 5 μM)]. (C) Representative
photomicrographs depict the migratory effect induced by histamine
and H4R agonist in N9 microglia cell line, an effect abolished in the
presence of the H4R antagonist. Data are expressed as mean± SEM
(n= 3-20) and as mean total number of cells migrating across the
scratch wound (*p< 0.05, **p< 0.01, ***p< 0.001, using Bonferroni’s
multiple comparison test).
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Figure 3 Histamine-induced motility requires α5β1 integrin involvement. (A) α5β1 integrin is expressed (in green) in the presence of LPS
(100 ng/ml) or histamine treatment (100 μM) observed by confocal microscopy. Nuclear labeling (in blue) was obtained with Hoechst 33342
staining. (B) Blockade of α5β1 integrin (α5β1 Ab neutralizing antibody: 10 μg/ml) impeded histamine-stimulated motility. (C) Representative
photomicrographs depict the migratory effect induced by histamine, which was abolished when α5β1 integrin was blocked. Data are expressed
as mean± SEM (n= 3-20) and as mean total number of cells migrating across the scratch wound (**p< 0.01, ***p< 0.001, using Bonferroni’s
multiple comparison test). Scale bar, 10 μm.
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formation of adhesion sites to the substrate [21,22]. For
this purpose, we immunolabeled alpha5/beta1 (α5β1) in-
tegrin and observed that upon LPS challenge or hista-
mine treatment, N9 microglial cells displayed a robust
α5β1 integrin expression (in green) on their cell surface
(Figure 3). Accordingly, when we blocked this integrin by
adding 10 ug/ml of the anti-α5β1 integrin-
neutralizing antibody, histamine-induced motility was
compromised (meanHIS100μM=174.4 ± 5.9 cells; meanHIS
+α5β1 = 110.3 ± 5.3 cells; p< 0.01, n= 3-13) (Figure 3B).
The neutralizing antibody against α5β1 alone did not
have any effect. Representative digital images depict the
histamine-induced migratory effect promoted by α5β1
integrin (Figure 3C). Other integrins, such as the integrin
α6 subunit, which forms a heterodimer with integrin β1
or β4, and recognizes laminin as a ligand, was not
involved in histamine-induced motility, as tested using a
neutralizing antibody directed against α6 subunit (data
not shown). Therefore, the integrin α5β1 is involved in
the pro-migratory effect induced by histamine in the N9
cell line.
Histamine-induced migration requires p38 and AKT
signaling pathways
We also addressed which signaling pathways could be
involved in our migration model (Figure 4). Given
that we have previously demonstrated the involve-
ment of p38 MAPK signaling in LPS-induced migra-
tion [16] and that the PI3K/Akt pathway has been
correlated with H4R-stimulated mast cell chemotaxis
[23] and with microglia migration [24,25], we evalu-
ated the effect of SB239063 (p38 inhibitor) and wort-
mannin (Akt inhibitor) on histamine-induced motility.
Accordingly, in the presence of 50 nM wortmannin,
both histamine- and H4R agonist-induced migration
were abolished (meanHIS+wort = 100.4 ± 3.4 cells;
meanH4R ag+wort = 95.1 ± 3.1 cells; p< 0.001, n = 3)
(Figure 4A). Similarly, pre-treatment with 20 μM
SB239063 inhibited both histamine- and H4R agonist-
induced migration (meanHIS+SB239063 = 95.0 ± 2.1 cells;
meanH4R ag+SB239063 = 102.8 ± 2.4 cells; p< 0.01, n = 3)
(Figure 4A). Neither wortmannin nor SB239063 alone
modulated microglia migration. These data suggest
that the p38 and AKT signaling pathways can be
involved in the migration induced by histamine or
H4R agonist per se.
Histamine H4 receptor activation modulates LPS-induced
microglia motility
We then decided to evaluate the role of histamine in an
inflammatory context and found that, upon LPS and his-
tamine co-administration, migration induced by LPS
alone was significantly inhibited (meanLPS = 167.0 ± 11.2
cells, meanHIS+LPS = 112.0 ± 5.7cells; p< 0.001, n= 7-13)
Figure 4 Histamine-induced migration requires p38 and Akt
signaling pathways. (A) In scratch wound assays, both histamine-
and H4R agonist-induced migration were inhibited in the presence of
Akt inhibitor, wortmannin (50 nM) or p38 inhibitor, SB239063 (20 μM).
(B) Representative photomicrographs depict the inhibitory effect on
migration induced by p38 and Akt signaling blockade. Data are
expressed as mean±SEM (n=3-20) and as mean total number of cells
migrating across the scratch wound (**p< 0.01, ***p< 0.001, using
Bonferroni’s multiple comparison test).
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(Figure 5A). The co-administration of histamine to-
gether with LPS did not induce cell death or prolifera-
tion (data not shown). Moreover, cells treated with both
histamine and LPS and in the presence of the H4R an-
tagonist displayed a motility rate similar to LPS alone-
treated microglia. The inhibition of LPS-induced migra-
tion by histamine is mediated by H4R activation, since in
the presence of H4R antagonist, the stimulatory effect
on migration is restored (meanHIS+LPS+H4R ant = 160.8 ±
11.2 cells; n= 3-15; p< 0.05, n= 4). Likewise, application
of H4R agonist significantly reduced LPS-induced motil-
ity (meanH4R Ag+LPS = 114.0 ± 7.7 cells; p< 0.01, n = 4).
Accordingly, none of the other receptor antagonists
interfered with the ability of histamine to reduce
LPS-stimulated migration (Figure 5A). Notably, his-
tamine-loaded microparticles (10 μg/ml) also inhib-
ited LPS-induced motility (meanuP10μg/ml
+LPS = 91.3 ± 22.5 cells; p< 0.001, n = 4). Representa-
tive digital images depict the inhibitory effect of his-
tamine on LPS-induced motility through H4R
activation (Figure 5B).
We later explored the role of histamine in a more
complex biological model that closely resembles the
physiological environment by using murine cortex
explants (Figure 6). Similarly to the in vitro cell line
model, we observed that histamine alone, acting through
H4R, or LPS alone stimulated migration of microglia/
CNS invading macrophages (meanCTR = 8.9 ± 2.8 cells;
meanHIS = 24.0 ± 6.5cells; meanH4R ag = 36.5 ± 9.1 cells;
meanLPS = 34.1 ± 7.4 cells; p< 0.05, p< 0.01, n= 5-9).
Moreover, exposure of explants to histamine or H4R
agonist, together with LPS, reduced migration, whereas
blockade of H4R, in this context, restored migration to
levels similar to the ones observed in LPS-treated cells
(meanHIS+LPS = 14.2 ± 4.5 cells; meanH4R ag+LPS = 13.2 ±
5.6 cells; meanHIS+H4R ant+LPS = 27.0 ± 3.9 cells; p< 0.05,
n= 5-8) (Figure 6B). Altogether, these data suggest that
histamine, in the presence of a robust inflammatory mi-
lieu induced by LPS, acting via H4R activation, drastic-
ally reduced microglia migration.
Application of the H4R antagonist restored LPS-stimu-
lated motility in the presence of histamine. Data are
expressed as mean±SEM (n=4-9) and as total number of
migrating CD11b-positive cells per explant area (number
of migrating CD11b-positive cells/mm2) (*p< 0.05, using
Bonferroni’s mu comparison test). Scale bar, 10 μm.
Histamine modulates proinflammatory cytokine release
Another key feature of inflammation is the release of sig-
naling proinflammatory cytokines, such as IL-1β and
tumor necrosis factor-alpha (TNF-α), by microglial cells
[26].
Using a quantitative method, ELISA, we analyzed
the release of IL-1β and TNF-α by N9 microglial
Figure 5 LPS-induced motility is inhibited by histamine via H4
receptor activation. (A) Upon an inflammatory challenge triggered
by LPS (100 ng/ml), 100 μM histamine inhibited migration, an effect
involving H4R activation. In the presence of histamine, only when
H4R was blocked (Ant H4R: JNJ7777120, 5 μM), LPS-induced
migration was restored. (B) Representative photomicrographs depict
the inhibitory effect of histamine on LPS-induced motility upon H4R
activation. Data are expressed as mean± SEM (n= 3-20) and as mean
total number of cells migrating across the scratch wound (*p< 0.05,
**p< 0.01, ***p< 0.001, using Bonferroni’s multiple comparison test).
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cell line (Figure 7A) and by hippocampal organoty-
pic slice cultures (Figure 7B). Regarding the cell line,
we observed that in the presence of LPS, there was a
significant release of biologically active IL-1β (mature
form) to the culture media (meanCTR = 138.5 ± 28.3
pg, meanLPS = 410.5 ± 96.2 pg; p< 0.01, n = 4-7)
(Figure 7A, left graph). LPS-induced release of IL-1 β
was abolished when cells were simultaneously treated
with histamine and LPS (meanHIS+LPS = 119.0 ± 28.0
pg; p< 0.01, n = 3). Application of the H4R agonist (20
μM) together with LPS mimicked the inhibitory effect
of histamine, whereas blockade of H4R (5 μM) abol-
ished histamine-induced inhibition of IL-1β release
(meanH4R ag = 72.1 ± 43.8 pg, meanH4R ag+LPS = 101.5 ±
64.4 pg, meanHIS+H4R ant+LPS = 534.1 ± 119.4 pg; p
< 0.01, p< 0.001, n = 3). Noteworthily, application of
histamine-loaded microparticles (10 μg/ml) had the
same inhibitory effect of histamine under an inflam-
matory challenge (meanuP10μg/ml+LPS = 142.7 ± 29.7
cells; p< 0.05, n = 3).
Interestingly, the inhibitory effect of histamine was not
observed over LPS-induced TNF-α release (Figure 7A,
right graph). LPS challenge stimulated TNF-α release;
however, histamine or histamine-loaded microparticles
had no effect on the release of this cytokine induced by
LPS (Figure 7A, right graph).
In hippocampal organotypic slice cultures, LPS signifi-
cantly increased IL-1β release (meanCTR = 17.6 ± 5.5 pg/
ml; meanLPS = 200.7 ± 37.4 pg/ml; p< 0.001, n= 8-11)
(Figure 7B, left graph). However, in the presence of his-
tamine or H4R agonist, LPS-induced release was mark-
edly reduced (meanHIS+LPS = 41.3± 4.2 pg/ml; meanH4R ag
+LPS = 37.1± 1.7 pg/ml; p< 0.001, n=4). Further enhan-
cing the involvement of H4R on this effect, the use of a
H4R antagonist partially restored the full LPS-induced
IL-1β release (meanHIS+H4R ant+LPS = 68.0 ± 9.4 pg/ml; p
< 0.05, n = 4) (Figure 7B, left graph). Histamine-loaded
microparticles did not decrease LPS-induced IL-1β re-
lease in this experimental model (data not shown).
Since using microwell inserts, where organotypic slices
are placed, does not allow an efficient interaction with
microparticles (particles will tend to deposit on the bot-
tom of the well), we did not pursue their application
further. In accordance with the previous data shown in
the N9 cell line, in hippocampal organotypic slice cul-
tures, TNF-α release remained unaffected by histamine
treatment (Figure 7B, right graph). LPS challenge sig-
nificantly increased TNF-α release, but histamine did
not reduce this effect.
Discussion
Historically, histamine has been mainly addressed as an
important mediator of allergic reactions occurring in per-
ipheral tissues. In recent years, with the discovery of new
histamine receptors and new sources of histamine in the
brain, it has become clear that histamine has an increas-
ingly defined role in the CNS. Regarding brain function,
histamine is involved in the modulation of biological
rhythms, sensory and motor systems, thermoregulation,
learning and memory, mood and feeding behavior [27].
However, little is known about the role of histamine in
brain inflammation. Most importantly, although microglial
cells have been identified as a source of histamine, there
Figure 6 Histamine promotes microglia/CNS macrophage
migration via H4 receptor activation in cortex explants. (A)
Representative confocal microscopy micrographs depict CD11b-
positive cells (in green) migrating from and within the explant, in the
presence of LPS treatment (100 ng/ml). Inset highlights microglia/
CNS macrophage morphology. (B) LPS and histamine individually
increased motility, while co-administration abolished this effect.
Likewise, in the presence of H4R agonist, LPS-induced motility was
also decreased.
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are few reports on how the activity/function of these cells
is modulated by this amine. As such, given the active
immunoregulatory role of microglial cells in the brain par-
enchyma, we sought to decipher the modulatory actions
of histamine over classical microglial responses, such as
migration and inflammatory mediator release. In our
study, we demonstrated that histamine, acting via H4R,
showed dual effects on microglia-induced responses. His-
tamine per se stimulated microglia motility, as compared
with untreated controls, and this migratory effect requires
the expression of α5β1 integrin and occurs with the in-
volvement of p38 MAPK and Akt signaling pathways. This
Figure 7 Histamine inhibits IL-1β release induced by LPS administration in N9 microglial cells (a) and in hippocampal organotypic slice
cultures (b) measured by ELISA. (a) N9 microglial cells, upon inflammatory challenge induced by LPS (100 ng/ml), are able to release a
significantly higher amount of proinflammatory cytokine IL-1β when compared to untreated cells. Histamine treatment (100 μM) significantly
inhibited this effect through the activation of H4R. Accordingly, histamine-loaded microparticles (μP 10 μg/ml) mimicked the anti-inflammatory
effect of histamine (left graph). The anti-inflammatory action of histamine appears to modulate specifically the IL-1β signaling pathway, since it
does not alter the release of another relevant proinflammatory cytokine, such as TNF-α, in the presence of 100 ng/ml LPS. Additionally, the
application of histamine-loaded microparticles (10 μg/ml) did not inhibit LPS-induced TNF-α release (right graph). (b) Regarding hippocampal
organotypic slice cultures, only soluble histamine significantly decreased IL-1β release induced by LPS. Again, H4R activation also mimicked the
effect of histamine, whereas H4R blockade partially recuperated LPS-induced IL-1β release (right graph). Data are expressed as mean± SEM
(n= 3-11), (*p< 0.05, **p< 0.01, ***p< 0.001, using Bonferroni’s multiple comparison test).
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effect suggests that histamine alone may function similarly
to an inflammatory mediator, although it does not change
the release of the cytokines IL-1β and TNF-α.
Importantly, it should be noted that microglial activa-
tion, a common feature of most brain pathologies, can be
coupled to either a pro- or anti-inflammatory profile and
exhibits several functionally distinct phenotypes. More-
over, since microglia continually surveys their micro-
environment, migration cannot be univocally associated
with a proinflammatory setting (as reviewed by [28]).
Of note, given an inflammatory context, such as our
experimental paradigm mimicked by the administration
of LPS, histamine inhibited microglial migration to levels
similar to control cultures. Moreover, histamine also
inhibited LPS-induced IL-1β release, although it did not
interfere with LPS-induced TNF-α release. Therefore, in
the presence of a strong and robust inflammatory con-
text, histamine may repress microglia-mediated migra-
tion and counteract additional tissue damage.
To our knowledge, we are the first to report the detec-
tion of H4R expression in both primary microglia cul-
tures from the cerebral cortex and in a microglia cell
line. To evaluate the role of histamine on microglial cell
migration, we adopted two experimental approaches,
with different degrees of complexity: scratch wound
assays and murine cortex explants. The use of scratch
wound assays allowed a complete pharmacological study
of the dual effect of histamine on cell migration, while
cortex explants offered a more physiological environ-
ment. Using these models, we observed that 100 μM his-
tamine and 10 μg/ml histamine-loaded microparticles
stimulated microglia migration. Histamine-loaded
microparticles can promote a more efficient and con-
trolled delivery of histamine, without cytotoxic effects
[13].
Moreover, we determined that this pro-migratory ef-
fect induced by histamine was occurring through H4R
activation. H4R is expressed mainly by immune cells
whose receptor activation modulates migration or cell
recruitment, calcium mobilization, cell differentiation
and cytokine production, depending on the cell type. In
particular, H4R induces chemotaxis of eosinophils, mast
cells, and dendritic and T cells, while reducing monocyte
recruitment (reviewed in [8]). In response to injury or
inflammation, microglial cells become activated and mi-
grate in a process that requires actin polymerization and
the upregulation of adhesion molecule CD11b, among
other adhesion molecules. In eosinophils, low concentra-
tions of histamine (below 10 mM) lead to actin
polymerization and significant CD11b upregulation, an
effect blocked by thioperamide, an H3R/H4R antagonist
[29]. Another key component required for cell move-
ment is the expression of integrins, a diverse family of
migration-inducing receptors, which are responsible for
cell-cell, cell-extracellular matrix (ECM) and cell-patho-
gen interactions [22,30]. Integrins are heterodimeric
complexes composed by different combinations of alpha
(α)/beta (β) subunits, which later define receptor specifi-
city. β1 integrin is the most widespread β subunit, and it
is involved in microglia chemotaxis and proliferation
[31]. In our work, we showed that α5β1 integrin block-
ade impaired histamine-induced migration, suggesting
that this heterodimer is required for microglia migration.
We should note that scratch wound assays were per-
formed without any substrate covering the bottom of
the wells. However, microglial cells are able to secrete
fibronectin, an α5β1 ligand (assessed by Western blot-
ting; data not shown), therefore enabling cell movement.
We further disclosed the mechanisms involved in hista-
mine-induced migration by evaluating the participation
of p38 mitogen-activated protein kinase and Akt signal-
ing pathways. We have previously demonstrated that
LPS-induced microglia migration requires p38 phosphor-
ylation [16]. In addition, H4R activation may rapidly and
transiently induce the phosphorylation of ERK, MEK and
Akt in other immune cell types [23-25]. Nevertheless,
using selective inhibitors of these pathways, SB239063
(p38 inhibitor) and wortmannin (Akt inhibitor), we
blocked histamine-induced migration, suggesting that
these pathways are required for cell movement.
To the best of our knowledge, there is only one report
suggesting crosstalk between alpha5beta1 integrin expres-
sion and p38/Akt pathways in cell migration. α5β1 and
αvβ3 integrin-mediated human umbilical vein endothelial
cell (HUVEC) adhesion to fibronectin or vitronectin acti-
vates integrin-dependent intracellular signaling cascades,
including PI3K/AKT, ERK, p38 and JNK, which subse-
quently lead to the stimulation of AP-1-dependent MMP-9
expression in HUVECs. However, the authors only showed
that blocking antibodies targeting α5β1 and αvβ3 integrins
abolished fibronectin-stimulated c-Jun phosphorylation,
while blocking antibodies targeting β1 and αvβ3 reduced
vitronectin-stimulated MMP-9 activity [32]. Nevertheless,
several studies showed some evidence of crosstalk among
integrins/MAPKs/Akt in cell invasion, although invasion
and migration are different processes since the latter does
not necessarily require invasion to occur [33-37].
There are several indications of H4R involvement in in-
flammatory disorders, including allergy, asthma, chronic
pruritus and rheumatoid arthritis, to name a few [8]. In our
study, we showed that histamine had a dual effect on
microglial cell migration. In a physiological context, hista-
mine, histamine-loaded microparticles or H4R agonist ap-
plication induced migration, whereas, in the presence of
LPS, these compounds had an inhibitory effect. Our results
were further validated using murine cortex explants, which
provided a more physiological environment to disclose the
effect of histamine in cell migration. Accordingly, we
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observed the same inhibitory action of histamine in the
presence of an inflammatory challenge using this model. In
that sense, H4R may have therapeutic value in the treat-
ment of inflammatory conditions or symptoms, although
histamine has been mainly regarded as a proinflammatory
agent. In fact, Smits and colleagues have designed and eval-
uated the role of several H4R ligands. The group found that
6,7-dichloro-3-(4-methylpiperazin-1-yl)quinoxalin-2(1 H)-
one and 2-benzyl-3-(4-methyl-piperazin-1-yl)quinoxaline
(two H4R agonists) displayed significant in vivo anti-inflam-
matory activity in the rat carrageenan-induced paw edema
model [38], validating the use of H4R ligands as anti-inflam-
matory agents in vivo. Furthermore, application of H4R
agonists has provided a reduction of asthma-like symptoms
due to enhanced migration of CD4+/CD25+/FoxP3+ T
regulatory cells (Tregs) to the inflammation site, where
these accumulated cells release the anti-inflammatory cyto-
kine IL-10 [39]. Additionally, Osna and colleagues reported
that histamine upregulates IL-10 production by murine
splenocytes in a dose-dependent manner; however, this ef-
fect was reversed by both H1- and H2-receptor antagonists
[40]. In addition, H4R activation prevents the development
of reperfusion injury in a model of ischemia-induced liver
damage [41]. Hence, our work extends the knowledge of
H4R activity and supports new perspectives on the use of
H4R agonists in a pathological context. Moreover, micro-
particle-mediated delivery of histamine or H4R agonists
might provide a new opportunity for the treatment of vari-
ous CNS disorders accompanied by microglia-derived in-
flammation. Nevertheless, it should be noted that the
majority of reports refer to the anti-inflammatory actions of
H4R antagonists in conditions such as pruritus, dermatitis,
airway inflammation and arthritis [8].
Cytokine signaling is a particularly relevant feature in
the local development of the inflammatory reaction, but
also in the recruitment of immune cells through the upre-
gulation of adhesion molecules and induction of chemo-
kines. In our study we evaluated the role of the pro-
inflammatory cytokines IL-1β and TNF-α in histamine-
modulated migration. We have previously described the
involvement of IL-1β signaling in LPS-induced microglia
migration in which we observed that blocking the IL-1 re-
ceptor led to the loss of the LPS pro-migratory effect [16].
However, IL-1 receptor blockade does not impair hista-
mine-induced migration, suggesting the involvement of
different migration mechanisms. Cells pre-treated with IL-
1ra (150 ng/ml) and incubated with histamine were still
able to migrate, although not entirely similarly to hista-
mine alone (meanHIS+ IL-1ra= 148± 5.8 cells; mean-
HIS= 174.4 ± 5.9 cells, n=3; data not shown), suggesting
that histamine does not require IL-1β signaling to induce
migration, but affects its release, possibly to control a
cytotoxic effect caused by the IL-1β release induced by a
strong LPS inflammatory stimulus [16]. Interestingly,
histamine per se does not modulate IL-1β release; how-
ever, it inhibited IL-1β release upon LPS challenge, an ef-
fect mimicked by H4R agonist. In organotypic slice
cultures, which include more complex cellular interactions
and different cell types (including neurons, astrocytes, oli-
godendrocytes and microglia), H4R blockade did not fully
restore LPS-induced IL-1β release in the presence of hista-
mine, suggesting the involvement of other receptors or
different modulation mechanisms by other types of cells
present in the slices. Our results suggest that in a healthy
brain parenchyma, exogenous application of histamine
would enhance the microglia surveillance, whereas, in an
inflammatory context, histamine would restrain microglia
motility while maintaining a putative anti-inflammatory
profile.
Importantly, it has been reported that in IL-1 receptor
1 (IL-1R1) null mice microglia activation is abrogated
when stab wounds are performed. The authors observed
that in the absence of IL-1R1, almost no reactive or
ameboid microglia are found, and leukocyte infiltration
is very reduced. Also, in these knockout mice, the pro-
inflammatory cytokine expression was decreased [42].
However, we did not observe TNF-α release upon hista-
mine or histamine microparticles in both experimental
models used.
Regarding TNF-α release, histamine has been
described to inhibit LPS-stimulated TNF-α release by
human monocytes, human and rat alveolar macro-
phages, and human peripheral blood mononuclear
cells [43-45]. In the studies performed by Sirois and
colleagues [44] and by Morichika and colleagues [45],
the LPS concentration ranged from 1–5 ng/ml, and
the histamine concentration ranged from 10-4-10-7 M;
their co-administration inhibited LPS-induced TNF-α
release. However, in the study developed by Rowe
and colleagues [43], human alveolar macrophages and
monocytes differed in their responses to histamine.
Histamine (10-5 M) inhibited LPS-stimulated (500 ng/
ml) TNF-α release by monocytes, but had no effect
on alveolar macrophages. These results suggest that
the inhibitory effect of histamine on LPS-induced
TNF-α release may depend on the LPS concentration
(we used 100 ng/ml) and on cell type. Noteworthily,
work performed by Desai and Thurmond [23] showed
that histamine and LPS co-treatment potentiated IL-6
release by mast cells, although it had no effect on
TNF-α release, suggesting that, depending on the
stimulus, different cells may present specific patterns
of response regarding cytokine release. Given the
unique properties of the brain parenchyma micro-
environment, it is reasonable to assume that although
microglial cells share a great deal of similarity with
monocytes/macrophages, they are endowed with a dif-
ferent range of signaling responses.
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Conclusions
Our results open promising new perspectives for the
therapeutic use of histamine and histamine receptor ago-
nists to treat or ameliorate inflammation-associated pro-
cesses. Histamine has been perceived as a major
inflammatory mediator in allergic responses. In accord-
ance, we showed that histamine can trigger microglia
motility per se, but not the release of the pro-inflamma-
tory cytokines IL-1β and TNF-α. Most importantly, we
have now revealed new anti-inflammatory properties of
histamine H4 receptor agonists that counteract LPS-
mediated inflammatory actions, namely motility/migra-
tion and IL-1β release by microglia/CNS invading
macrophages. Therefore, the use of histamine-loaded
microparticles (or ultimately, microparticles loaded
with H4R agonists) could provide a rapid, more effi-
cient and affordable approach in an inflammatory
context.
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